FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
Publishing timestamp: 2024-04-30 13:48:23
Summary
The Federal Trade Commission is challenging alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's diabetes drugs. The FTC argues that drugmakers are listing extra patents to keep drug prices high and stall generic competitors, in an effort to make healthcare more affordable for Americans.
Sentiment: NEGATIVE
Tickers: TEVA-IL, NVO, NVS, GSK, AZN, AMPH, NOVO.B-DK, NOV.N-CH, TEVA, GSK-GB, AZN-GB,
Keywords: astrazeneca plc, breaking news: politics, social issues, breaking news, novartis ag, products and services, joe biden, pharmaceuticals, business, business news, health care industry, amphastar pharmaceuticals inc, politics, teva pharmaceutical industries ltd, biotech and pharmaceuticals, novo nordisk a/s, biotechnology, gsk plc,
Source: https://www.cnbc.com/2024/04/30/ftc-challenges-patents-held-by-drugmakers-including-for-ozempic.html